NCT06703060

Brief Summary

U.S. epidemiological data indicates that Black women are a high-risk HIV disparity group, yet initiation of novel prevention strategies like pre-exposure prophylaxis (PrEP) among this group is stagnant. Socio-structural challenges like intimate partner violence and gendered racism can constrain PrEP access among Black women, but few implementation studies have mitigated these challenges to improve PrEP initiation. The proposed research aims to implement and assess the effectiveness, implementation, and sustainability of a multilevel intervention to increase PrEP initiation among Black women with and without intimate partner violence in Baltimore.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
22mo left

Started Feb 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
Feb 2025Feb 2028

First Submitted

Initial submission to the registry

November 7, 2024

Completed
18 days until next milestone

First Posted

Study publicly available on registry

November 25, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

February 28, 2025

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

2.8 years

First QC Date

November 7, 2024

Last Update Submit

March 19, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • PrEP initiation

    Self-report of oral or injectable PrEP (Cabotegravir). Assessed from date of the most recent prescription.

    Post baseline up to 6 months

Secondary Outcomes (1)

  • PrEP adherence

    2-months post-randomization, 4-months post-randomization, and 6-months post-randomization

Study Arms (2)

Intervention Group (Peer Navigation)

EXPERIMENTAL

Participants randomized to this arm will receive 4 weekly group sessions and 4 one-on-one sessions with a peer navigator

Behavioral: Peer Navigation Group

Control Group

PLACEBO COMPARATOR

Participants randomized to this group will receive a single group session

Behavioral: Peer Navigation Group

Interventions

Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.

Control GroupIntervention Group (Peer Navigation)

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsCisgender Black women (Black women who were born with female genital and also identify as women)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • self-identified Black cisgender woman;
  • self-reported HIV-negative status, and
  • ≥18 years.
  • reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner,
  • have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and
  • never taken PrEP

You may not qualify if:

  • non-English speaking and
  • currently living with HIV

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, 21205, United States

RECRUITING

Study Officials

  • Tiara C. Willie, PhD, MA

    Johns Hopkins Bloomberg School of Public Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tiara C. Willie, PhD, MA

CONTACT

Project Director, DrPH

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2024

First Posted

November 25, 2024

Study Start

February 28, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

February 1, 2028

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to privacy, confidentiality, and ethical considerations. Protecting personal information is essential to comply with privacy laws (e.g., HIPAA) and the terms of informed consent. Sharing such data could breach confidentiality agreements and potentially expose sensitive information, even if anonymized. Additionally, there are concerns about data security, misuse, and the potential harm to participants, which researchers must carefully consider.

Locations